{"id":32506,"date":"2025-07-30T08:43:10","date_gmt":"2025-07-30T08:43:10","guid":{"rendered":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/"},"modified":"2025-07-30T08:43:10","modified_gmt":"2025-07-30T08:43:10","slug":"estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/","title":{"rendered":"Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se eval\u00faa la administraci\u00f3n adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusi\u00f3n en el gen RET (LIBRETTO-432)"},"content":{"rendered":"<p>MANUEL COBO DOLS &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; LILLY, S.A.<\/p>","protected":false},"excerpt":{"rendered":"<p>MANUEL COBO DOLS &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; LILLY, S.A.<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2683],"tags":[],"class_list":["post-32506","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-b-22"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se eval\u00faa la administraci\u00f3n adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusi\u00f3n en el gen RET (LIBRETTO-432) - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se eval\u00faa la administraci\u00f3n adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusi\u00f3n en el gen RET (LIBRETTO-432) - Ibima\" \/>\n<meta property=\"og:description\" content=\"MANUEL COBO DOLS &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; LILLY, S.A.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:43:10+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se eval\u00faa la administraci\u00f3n adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusi\u00f3n en el gen RET (LIBRETTO-432)\",\"datePublished\":\"2025-07-30T08:43:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\\\/\"},\"wordCount\":55,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - B-22\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\\\/\",\"name\":\"Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se eval\u00faa la administraci\u00f3n adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusi\u00f3n en el gen RET (LIBRETTO-432) - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:43:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se eval\u00faa la administraci\u00f3n adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusi\u00f3n en el gen RET (LIBRETTO-432)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/en\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se eval\u00faa la administraci\u00f3n adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusi\u00f3n en el gen RET (LIBRETTO-432) - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/","og_locale":"en_GB","og_type":"article","og_title":"Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se eval\u00faa la administraci\u00f3n adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusi\u00f3n en el gen RET (LIBRETTO-432) - Ibima","og_description":"MANUEL COBO DOLS &#8211; ENSAYO CLINICO COMERCIAL &#8211; III &#8211; LILLY, S.A.","og_url":"https:\/\/ibima.eu\/en\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:43:10+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se eval\u00faa la administraci\u00f3n adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusi\u00f3n en el gen RET (LIBRETTO-432)","datePublished":"2025-07-30T08:43:10+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/"},"wordCount":55,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - B-22"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/","url":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/","name":"Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se eval\u00faa la administraci\u00f3n adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusi\u00f3n en el gen RET (LIBRETTO-432) - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:43:10+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/estudio-de-fase-3-aleatorizado-doble-ciego-controlado-con-placebo-en-el-que-se-evalua-la-administracion-adyuvante-de-selpercatinib-tras-un-tratamiento-locorregional-definitivo-en-participantes-con\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, en el que se eval\u00faa la administraci\u00f3n adyuvante de selpercatinib tras un tratamiento locorregional definitivo en participantes con CPNM en estadio IB-IIIA que presentan fusi\u00f3n en el gen RET (LIBRETTO-432)"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/en\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/32506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=32506"}],"version-history":[{"count":3,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/32506\/revisions"}],"predecessor-version":[{"id":55559,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/32506\/revisions\/55559"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=32506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/categories?post=32506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/tags?post=32506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}